Patients with completely resected stage IA NSCLC, in which vessel invasions are observed
Conditions
Interventions
From four to eight week, adjuvant chemotherapy with UFT start until 2 years
Sponsors
Lung Oncology Group in Kyushu, Japan (LOGIK)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1.Patients with obtained informed consent 2.Non-small cell lung cancer (NSCLC) with histological proof 3.Pathological stage IA NSCLC after complete resection(include intensive limited resection)4.Positive lymphatic or blood vessel invasion 5.First therapy 6.No prior treatment except for surgery 7.Age=>45and <80 years 8.No active double cancer 9.Patients who can be orally administrated 10.Performance status 0 or 1 11.Patients also had to have adequate organ function (within 14 days before entry 4000=<leukocytes=<12,000/mm3, Hemoglobin>=10.0g/dl thrombocytes>=100,000/mm3 GOT and GPT less than twice the normal limits at each institution blood urea nitrogen=<25 mg/dl creatinine less than the normal limits at each institution
Exclusion criteria
Exclusion criteria: 1.Patients with drug allergy 2. Patients with contraindication of UFT administration 3.Patients with severe complication (bowel paralysis,ileus,pneumonia,emphysema,lung fibrosis or interstitial pneumonia,uncontrollable DM,heart failure,renal failure,and liver failure)4.Patients with watery diarrhea 5.Women who have possibility(will)with gestation and pregnant or breast feeding women 6.Men who have will with making bady 7.Doctor judged inadequate patients
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 5-year survival rate | — |
Secondary
| Measure | Time frame |
|---|---|
| Completion rate, recurrent rate, drug toxicity, 3-year survival rate, 3- and 5-year disease free survival rates. | — |
Countries
Japan
Contacts
Public ContactAkamine Shinji
Oita Prefectural Hospital Chest surgery
Outcome results
None listed